top of page


AGC Biologics expands dual-site pharmaceutical manufacturing contract to more than €500 million
AGC Biologics has expanded a long-term manufacturing agreement with an unnamed global pharmaceutical company to more than €500 million, adding six commercial biologics programmes at its Copenhagen facility.

nuaxia
Nov 42 min read


Gland Pharma signs global sterile injectables CDMO deal with $90–100 million annual revenue potential
The long-term manufacturing agreement covers 55 oncology and non-oncology products across three Gland Pharma sites, with commercial revenue expected to begin in 2029.

nuaxia
Aug 102 min read
bottom of page